Harman Finochem Ltd, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their notable products is CARISOPRODOL USP, with a corresponding US DMF Number 21064.
Remarkably, this DMF maintains an Active status since its submission on November 27, 2007, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of January 31, 2013, and payment made on January 03, 2013, indicating their dedication to facilitating drug approvals, Categorized as Type II